5-Fluorouracil-Loaded BSA Nanoparticles: Formulation Optimization and In Vitro Release Study

被引:83
作者
Maghsoudi, Amir [1 ]
Shojaosadati, Seyed Abbas [1 ]
Farahani, Ebrahim Vasheghani [1 ]
机构
[1] Tarbiat Modares Univ, Dept Chem Engn, Fac Engn, Biotechnol Grp, Tehran, Iran
基金
美国国家科学基金会;
关键词
5-fluorouracil; BSA; drug release; nanoparticle; optimization;
D O I
10.1208/s12249-008-9146-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Over the past few decades, there has been considerable interest in developing protein nanoparticles as drug delivery devices. The underlying rationale is their exceptional characteristics, namely biodegradability and nonantigenicity. Herein, phase separation method was used to prepare 5-fluorouracil-loaded bovine serum albumin (BSA) nanoparticles. Drug release was tracked by continuous flow dialysis technique. Effect of process variables on loading efficiency of 5-fluorouracil was investigated and optimized through Taguchi's M16 design with the amount of entrapped drug as response. Optimum condition was found to be 2 mg/mL of 5-fluorouracil, 3.7 mL of added ethanol, 176 mu L of glutaraldehyde, drug-protein incubation time of 30 min, and pH of 8.4 for 200 mg of BSA in 2 mL drug solution. pH had the most noticeable effect on the amount of entrapped drug, but glutaraldehyde had the least. Mean diameter and zeta potential of fabricated nanoparticles under these conditions were 210 nm and -31.7 mV, respectively. Drug-loaded BSA nanoparticles suspension maintained constant release of drug for 20 h under experimental conditions, so this colloidal drug carrier is capable of releasing drug in a sustained manner.
引用
收藏
页码:1092 / 1096
页数:5
相关论文
共 24 条
  • [1] PREPARATION AND CHARACTERIZATION OF 5-FLUOROURACIL-LOADED MICROPARTICLES AS BIODEGRADABLE ANTICANCER DRUG CARRIERS
    BOISDRONCELLE, M
    MENEI, P
    BENOIT, JP
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1995, 47 (02) : 108 - 114
  • [2] Bozkir Asuman, 2005, Farmaco (Lausanne), V60, P840, DOI 10.1016/j.farmac.2005.06.016
  • [3] Methods to assess in vitro drug release from injectable polymeric particulate systems
    D'Souza, SS
    DeLuca, PP
    [J]. PHARMACEUTICAL RESEARCH, 2006, 23 (03) : 460 - 474
  • [4] DSOUZA SS, 2005, AAPS PHARMSCITECH, V62, pE323
  • [5] PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release
    Faisant, N
    Siepmann, J
    Benoit, JP
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 15 (04) : 355 - 366
  • [6] Jaeghere D., 1999, ENCY CONTROLLED DRUG, P641
  • [7] KOSTANSKI JW, 2000, AAPS PHARMSCITECH, V11, P4
  • [8] Microsphere design for the colonic delivery of 5-fluorouracil
    Lamprecht, A
    Yamamoto, H
    Takeuchi, H
    Kawashima, Y
    [J]. JOURNAL OF CONTROLLED RELEASE, 2003, 90 (03) : 313 - 322
  • [9] Optimization of the preparation process for human serum albumin (HSA) nanoparticles
    Langer, K
    Balthasar, S
    Vogel, V
    Dinauer, N
    von Briesen, H
    Schubert, D
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 257 (1-2) : 169 - 180
  • [10] Pharmacokinetic characteristics and anticancer effects of 5-Fluorouracil loaded nanoparticles
    Li, Su
    Wang, Anxun
    Jiang, Wenqi
    Guan, Zhongzhen
    [J]. BMC CANCER, 2008, 8 (1)